Our portfolio company NovaGo Therapeutics announced that its academic collaboration partner the Nogo-A Inhibition in Spinal Cord Injury Study Group (NISCI) published the results of the investigation of the anti-Nogo-A antibody NG101 in acute spinal cord injury patients in Lancet Neurology. NovaGo’s founder and CSO Prof. Martin Schwab initiated the NISCI consortium. The phase 2 study has shown early signs of disease modifying effects for the treatment of acute spinal cord injuries. NovaGo started the clinical development of a new and improved anti-Nogo-A antibody NG004. We are excited continuing the journey to bring regenerative therapies to acute spinal cord injury patients. https://lnkd.in/ecFBzEqH
Pureos Bioventures
Wagniskapital- und Private-Equity-Auftraggeber
Pfäffikon, Schwyz 2.389 Follower:innen
Pureos is a venture capital fund investing in private innovative drug development companies
Info
Pureos Bioventures is a venture capital fund, which invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.
- Website
-
http://www.pureosbio.com
Externer Link zu Pureos Bioventures
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Pfäffikon, Schwyz
- Art
- Personengesellschaft (OHG, KG, GbR etc.)
Orte
-
Primär
Churerstrasse 47
Pfäffikon, Schwyz 8808, CH
Beschäftigte von Pureos Bioventures
Updates
-
We are thrilled to welcome Citryll to our portfolio! Pureos Bioventures participated in the €85 million Series B financing round, supporting Citryll’s mission to advance groundbreaking NET-targeting therapies. This funding will enable Citryll to advance CIT-013, a first-in-class monoclonal antibody, into Phase 2a clinical trials for rheumatoid arthritis (RA) and hidradenitis suppurativa (HS). By targeting Neutrophil Extracellular Traps (NETs), their innovative approach tackles chronic inflammation, offering new hope for patients where current therapies fall short. https://lnkd.in/duuMnhNR
Citryll Raises EUR 85 Million Series B To Advance Novel NET-Targeting Therapy For Immune-Mediated Inflammatory Disorders
https://citryll.com
-
Our portfolio company Ariceum Therapeutics announces a global supply agreement with Eckert & Ziegler SE for medical radionuclides Actinium-225 and Lutetium-177, to reliably deliver next-generation radiotherapeutics to patients! This collaboration enables them to build a robust supply chain and continue to develop their pipeline, with the lead asset Satoreotide - a first-in-class antagonist of the somatostatin receptor 2 labelled with Ac-225, ready to enter clinical development in small cell lung cancer and Merkel Cell Carcinoma.
Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
https://ariceum-therapeutics.com
-
Read below Pureos Managing Partner Dominik Escher recent interview with PharmaBoardroom with interesting insights into the Swiss biotech ecosystem, Pureos strategy, and its leadership role in supporting Swiss innovation. https://lnkd.in/dzgBNAF7
Dominik Escher - Managing Partner, Pureos Bioventures
https://pharmaboardroom.com
-
Leadership Update at Minervax ApS: We are thrilled to announce that Veronica Gambillara Fonck will serve as the new Chair of the Board of Directors of our portfolio company Minervax ApS, in addition to her role as a Partner at Pureos Bioventures! With over 18 years in biotech and pharma, Veronica brings invaluable expertise in vaccine development, strategic growth, and leadership. Her appointment marks an exciting phase as MinervaX advances toward Phase III trials with their novel GBS vaccine for maternal health. A special thanks to former Chair Gerd Zettlmeissl for his pivotal role in MinervaX's journey. With Veronica’s vision and experience, we are convinced that MinervaX is poised to make a profound impact on maternal and infant health worldwide.
Biotech Entrepreneur Veronica Gambillara Fonck Appointed Chair of MinervaX | MinervaX
https://minervax.com
-
We are excited to share the closing of the Series D financing of our portfolio company, Alentis Therapeutics, raising $181.4 million to fund the development of its first-in-class anti-Claudin-1 ADCs for solid tumors with Phase 1/2 studies for ALE.P02 and ALE.P03 commencing in 2025. https://lnkd.in/eVSGPG5G
Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors - Alentis Therapeutics
https://alentis.ch
-
Exciting news from our portfolio company PulseSight Therapeutics with new developments in the fight against Geographic Atrophy (GA) and Age-related macular degeneration (AMD)! PulseSight Therapeutics has just presented breakthrough data at the EVER Congress 2024 on PST-611, its first-in-class, vectorized therapy targeting dry AMD and Geographic Atrophy. This innovative therapy uses human transferrin to address excess iron toxicity - a key driver of inflammation and cell death in GA. Promising results show that PST-611 restores iron balance, protects retinal cells, and offers a safer, minimally invasive approach to treating progressive vision loss. We look forward to closely following the continued advancements in the fight against eye diseases! https://lnkd.in/dPanpgux
PulseSight Therapeutics Presents New Data on PST-611 Transferrin Vectorized Therapy for Geographic Atrophy at EVER Congress 2024
https://pulsesight.com
-
Reflecting on a great Festival of Biologics 2024 in Basel! It was a fantastic event filled with thought-provoking panels, dynamic discussions, and the perfect opportunity to reconnect with familiar faces and to build new relationships. It was a pleasure to join the panel discussion in finance & investment for Start-ups with Dominik Escher, Managing Partner representing Pureos Bioventures and the very insightful keynote panel discussion “Accelerating ADC and Bioconjugate Development" with Dragan Grabulovski (Araris Biotech AG) and Jack Elands (Adcytherix) representing two Pureos Portfolio companies. Looking forward to the Festival of Biologics 2025!
-
Exciting news from our portfolio company PulseSight Therapeutics! We're thrilled to announce that their team will present groundbreaking data on PST-611 at the 2024 EVER Congress in Valencia, Spain. PST-611 is a new possible treatment against geographic atrophy (GA) secondary to dry AMD by restoring iron homeostasis to protect retinal cells. The company is about to submit a clinical trial authorization (CTA) by end October to start clinical development of this exciting new mode of action in GA. Join PulseSight for: Oral Presentation by Dr. Thierry Bordet (CSO) on November 5th, 2024; 09:20-10:35 CET Poster Presentation by Dr. Karine BIGOT on November 5th, 2024; 11:05-12:05 CET
PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024
globenewswire.com
-
We are thrilled to announce that our portfolio company Alentis Therapeutics has received FDA IND clearance for ALE.P02, a first-in-class Claudin-1 antibody-drug conjugate (ADC) designed to target squamous cancers. This marks a significant milestone as ALE.P02 becomes the first anti-Claudin-1 ADC to enter the clinic. Alentis' innovative approach has the potential to address critical unmet needs in cancer treatment, and the company will start the Phase 1 clinical trial in patients in Q1 2025. Congrats to the Alentis team! https://lnkd.in/eQU3Hd5y
Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers - Alentis Therapeutics
https://alentis.ch